Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 29 01:24PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)- Insider Own29.60% Shs Outstand76.67M Perf Week2.74%
Market Cap1.25B Forward P/E- EPS next Y-1.38 Insider Trans0.00% Shs Float70.81M Perf Month10.63%
Income- PEG- EPS next Q-0.34 Inst Own44.56% Short Float11.20% Perf Quarter47.50%
Sales- P/S- EPS this Y-316.50% Inst Trans2.33% Short Ratio16.31 Perf Half Y3.60%
Book/sh3.10 P/B4.00 EPS next Y-7.36% ROA- Short Interest7.93M Perf Year46.28%
Cash/sh3.85 P/C3.22 EPS next 5Y13.15% ROE- 52W Range5.90 - 13.14 Perf YTD17.66%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-5.71% Beta0.69
Dividend TTM- Quick Ratio3.18 Sales past 5Y198.55% Gross Margin- 52W Low110.00% ATR (14)0.51
Dividend Ex-Date- Current Ratio3.18 EPS Y/Y TTM111.37% Oper. Margin8.49% RSI (14)63.41 Volatility3.96% 3.93%
Employees293 Debt/Eq0.16 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price19.47
Option/ShortYes / Yes LT Debt/Eq0.06 EPS Q/Q-122.80% Payout0.00% Rel Volume0.34 Prev Close12.44
Sales Surprise-45.16% EPS Surprise11.90% Sales Q/Q-94.42% EarningsNov 14 BMO Avg Volume486.29K Price12.39
SMA206.44% SMA5010.05% SMA20014.71% Trades Volume103,621 Change-0.40%
Date Action Analyst Rating Change Price Target Change
Nov-02-23Initiated Cantor Fitzgerald Overweight
Mar-31-23Initiated Mizuho Buy $12
Mar-24-23Initiated Bryan Garnier Buy $16
Nov-20-20Initiated BofA Securities Buy $13
Sep-22-20Initiated Goldman Buy $17
Jul-27-20Initiated SVB Leerink Outperform $17
Jul-24-20Initiated Jefferies Buy
Jan-17-24 08:30PM
Jan-16-24 03:59AM
Nov-30-23 04:00AM
Nov-14-23 07:00AM
07:00AM Loading…
Nov-08-23 07:00AM
Oct-24-23 07:00AM
Sep-12-23 06:50AM
Sep-11-23 07:00AM
Aug-17-23 07:00AM
Aug-10-23 07:00AM
Jul-24-23 07:00AM
May-16-23 07:00AM
May-02-23 07:00AM
May-01-23 07:00AM
08:56AM Loading…
Apr-23-23 08:56AM
Mar-21-23 07:31AM
Nov-17-22 07:00AM
Oct-10-22 07:37AM
Sep-10-22 03:06AM
Aug-23-22 07:00AM
Aug-09-22 07:00AM
Jun-25-22 10:42AM
Jun-07-22 07:00AM
Jun-02-22 07:05AM
May-26-22 06:54AM
May-18-22 07:00AM
May-10-22 07:00AM
11:41AM Loading…
May-03-22 11:41AM
Apr-15-22 09:55AM
Mar-31-22 12:13PM
Mar-23-22 07:00AM
Feb-14-22 09:54AM
Dec-16-21 04:42AM
Dec-14-21 06:59AM
Nov-18-21 08:01AM
Nov-16-21 07:00AM
Nov-09-21 08:00AM
Nov-01-21 08:00AM
Aug-20-21 07:31AM
Aug-10-21 07:00AM
Jul-07-21 03:00AM
May-26-21 07:00AM
May-22-21 04:29AM
May-18-21 07:00AM
May-11-21 07:00AM
Apr-03-21 05:41AM
Mar-30-21 07:00AM
Mar-17-21 07:00AM
Mar-02-21 03:00AM
Dec-18-20 04:30PM
Dec-02-20 07:00AM
Nov-10-20 07:00AM
Oct-29-20 07:00AM
Oct-14-20 06:19PM
Oct-05-20 11:23AM
Sep-30-20 10:01AM
Sep-29-20 07:00AM
Sep-15-20 07:00AM
Sep-10-20 07:00AM
Sep-03-20 07:00AM
Aug-18-20 07:00AM
Aug-06-20 07:00AM
Jul-09-20 07:00AM
Jul-02-20 07:00AM
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline include adoptive cell therapy and TCR Bispecifics.The company was founded on March 10, 2020 and is headquartered in Tuebingen, Germany.